U.S. pharma large copyright scrapped two experimental weight loss supplements final yr—a after-day-to-day tablet, lotiglipron, due to elevated liver enzymes along with a twice-everyday capsule, danuglipron, due to robust Unwanted effects—but CEO Albert Bourla has claimed the company is set to “Participate in and earn” within the obesity spa